High Anti-Tumour Necrosis Factor Trough Concentrations--Only a Cost Issue or Also Hidden Dangers Ahead?
KU Leuven - University of Leuven, Therapeutic and Diagnostic Antibodies, Leuven, Belgium University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA niels.vandecasteele@kuleuven.be.
Niels
N
Vande Casteele
University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium.
Séverine
S
Vermeire
D000068879:Adalimumab / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics*; D001172:Arthritis, Rheumatoid / Q000209:etiology*; D005260:Female; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000493:pharmacokinetics*; D060046:Maintenance Chemotherapy / Q000009:adverse effects*; D008297:Male; D011565:Psoriasis / Q000209:etiology*; D011788:Quality of Life
D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab
Trough levels; arthralgia; paradoxical inflammation; skin lesions